Navigation Links
Implications of Statin Therapy in Bladder Cancer Patients

Smoking is one of the major risk factors for the development of bladder cancer and is also associated with cardiac disease, hyperlipidemia, and atherosclerosis.//

Consequently, it is not uncommon for patients with bladder cancer to have concomitant cardiac disease and hyperlipidemia. The 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used in the treatment of hyperlipidemia and, in fact are available as over the counter drugs in some countries due to a perceived significant impact on overall mortality from cardiac disease.

In the January issue of the New England Journal of Medicine, Hoffmann and colleagues reported on a series of patients with bladder cancer who were treated with BCG. Of the 84 patients, 19 were also receiving statin therapy. After a median follow-up of 46 months, it appeared that patients receiving statin therapy had a higher incidence of disease progression (10 of 19 (53%) versus 12 of 65 (18%), p = 0.004). The number of recurrences did not differ significantly between the groups. While a larger number of patients on statin therapy underwent radical cystectomy, among the patients who underwent radical cystectomy, the number in whom metastases developed and the time to their development were similar in the two groups. The authors concluded that 'Our observations suggest that the discontinuation of statin therapy during BCG immunotherapy might improve the clinical outcome'.

In the March issue of NEJM, Kamat and Wu reported on the outcomes of a cohort of 156 patients who received BCG treatment; 39 took statins during BCG, and 117 did not. After a median follow-up: 56 months, there was no difference in recurrences (59% in both groups, p = 0.801), tumor progression (30% vs. 28%, p = 0.57) or deaths. Furthermore, there was no difference in outcomes, even when accounting for whether patients received only induction BCG therapy or induction BCG plus maintenance therapy.

At the current time, treating urologists and patients should view the available data as inconclusive, at best. This is especially important since patients with bladder cancer commonly use statins, and some reports have documented antiproliferative effects of statins urothelial cancer cell lines. Further more, since it has been shown that discontinuation of statin therapy can have adverse cadiac outcomes, it seems prudent to continue statin therapy in bladder cancer patients who are on BCG, until more robust data to suggest otherwise are presented.

Source-Newswise
'"/>




Related medicine news :

1. Genetic Eye Disorder Can Have Other Implications
2. New Way to Open Cellular Ion Channels, Implications for Drug Design
3. Statins reduce heart attacks
4. Statins reduce risks for angioplasty patients
5. Statins Found To Be Helpful For Patients With Arthritis
6. Long-Term Benefits Of Statins Questioned
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Use of Statin can help in recovery from stroke
9. Statins Not Effective In Treating Calcific Aortic Stenosis
10. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
11. The Effects of Statins Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate , founder ... money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed ... James saw firsthand the effect of the critical funding gap for research into pediatric ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top ... Cynthia Murdock and Dr. Shaun Williams have each been chosen by their peers ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Bill Howe ... collaboration with the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest ... healthy and active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures ... **An FDAnews Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, ... Century Cures Act in order to thrive this year? , The passage of the ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: